New Markers May Help Predict Course of Prostate Carcinoma

Oncology NEWS InternationalOncology NEWS International Vol 4 No 10
Volume 4
Issue 10

SEATTLE-Current screening techniques allow the early detection of prostate cancer in large numbers of men every year. The problem is that prostate cancer appears to be an almost ubiquitous malignancy in men over the age of 50. The question, then, is which patients require intervention to prevent their cancer from becoming life threatening?

SEATTLE-Current screening techniques allow the early detectionof prostate cancer in large numbers of men every year. The problemis that prostate cancer appears to be an almost ubiquitous malignancyin men over the age of 50. The question, then, is which patientsrequire intervention to prevent their cancer from becoming lifethreatening?

Three commonly used parameters are somewhat helpful in this regard:Gleason grade, tumor volume, and extent of tumor infiltration,said Michael Brawer, MD, of the University of Washington, Seattle.

In his presentation at the Pacific Northwest Cancer FoundationMeeting on Transperineal Brachytherapy for Early Stage ProstateCancer, Dr. Brawer noted that a number of new markers such asoncogenes and tumor microvasculariza-tion are currently beingevaluated.

Histologic (Gleason) grading does work, he said, in predictingthe probability of metastasis. The problem is, the majority ofcancers that are detected by early screening fall into a middleground where the picture is not so clear.

He said that tumor volume is also helpful in predicting metastaticdisease and seminal vesicle invasion. But it is difficult to assessthe shape and volume of a tumor by remote methods. Although transurethralultrasound (TRUS) is helpful in visualizing the extent of thetumor outside of the capsule, it is not otherwise useful in stagingthe cancer. "Pathologic stage and echogenicity may indicatehigher grade cancer," Dr. Brawer said, "but so far wehaven't seen any difference."

Biopsy is used to determine the extent of the tumor, ie, whetherthe cancer is found on one side of the prostate (B1), both sides(B2), or shows extracapsular extension. The more biopsy sitesthat contain cancer cells, the larger the tumor volume, whichworsens the prognosis.

The best combination at present for determining prostate cancerprognosis is biopsy, histological staging, and PSA values, hesaid.

The position of the tumor may have some predictive value, butnot a great deal. "Prostate cancer likes to escape the glandalong the neurovascular bundle," Dr. Brawer said. "Cancerin the apex has a preferred position for exiting, so this maybe a slightly worse area to find the tumor, but this hasn't beenhighly predictive." He noted that DNA heterogeneity (ploidy)also has not proved to be useful.

Newer Techniques

An area that needs further study is that of neuroendocrine differentiationof the tumor, Dr. Brawer said. Apparently an increase in the subsetof prostate cancer cells that express neuroendocrine markers hasbeen correlated with an increased rate of tumor progression insome studies, but others have shown no such correlation. Expressionof the oncogenes bcl-2 and p53 may also indicate greater tumorprogression, but again results have been mixed.

A parameter that seems especially promising, Dr. Brawer said,is the extent of microvascularization of a particular tumor. "Tumorangiogenesis is extremely important," he said. "Oncea neoplasm is greater than 1 mm in diameter, it has to inducea blood supply from the surrounding tissue."

Dr. Brawer and his colleagues have quantitated microvessel densityvia computer and correlated this with pathologic stage. They foundthat this technique yielded a significant increase in their abilityto detect which cancers had progressed beyond the prostate, particularlywhen microvessel density was more than 120 vessels/mm.

Another technique for detecting ex-traprostatic disease that hasshown good preliminary results uses reverse transcriptase PCR(polymerase chain reaction), Dr. Brawer said. The researchersused primers against PSA and prostate membrane antigen to probefor small numbers of circulating cancer cells.

"There's nothing new here," he said. "We've knowncancer cells circulate. The question is, are these circulatingcells able to give rise to metastases and predict a negative outcome?"

Dr. Brawer noted that the PCR technique thus far is about 72%to 88% as sensitive as PSA levels in predicting extraprostaticmetastases. These are encouraging results, but he noted that furthermarkers need to be developed to prove that those cancer cellsthat can be detected actually have the potential to cause metastaticmalignancy.

Related Videos
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Alicia K. Morgans, MD, MPH, from Dana-Farber Cancer Institute indicates that patients with non-metastatic castration-resistant prostate cancer are able to stay on treatment for long periods of time with darolutamide vs enzalutamide and apalutamide.
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Related Content